First-line nivolumab plus ipilimumab in kidney cancer patients without nephrectomy
A recent post hoc analysis of the CheckMate 214 trial [...]
A recent post hoc analysis of the CheckMate 214 trial [...]
A recent study published in Journal of Clinical Medicine this [...]
The use of two medicines together (combination therapies) for previously [...]
Ipilimumab plus nivolumab is a standard first-line treatment for patients [...]
Recent evidence suggests that the bacteria in the gut (the [...]
Brain metastases resulting from the spread of renal cell carcinoma [...]
Long-term follow-up data from the CheckMate-214 study of the nivolumab [...]
Data from the CheckMate-920 study on the safety and effectiveness [...]
Four-year follow up data are now available from the CheckMate [...]
Further results from the ongoing CheckMate 214 phase III study [...]